Case: Bristol-Myers Squibb Canada Co v Teva Canada Limited, 2017 FCA 76 (A-191-16), aff’g (for different reasons) 2016 FC 580 (Court File No. T-1364-14)
Drug: REYATAZ® (atazanavir bisulfate)
Nature of case: Appeal from application for prohibition order granted
Case: Apotex Inc v Her Majesty the Queen, 2017 FCA 73 (Court File No. A-553-14/A-554-14)
Drug: Apo-Trazodone
Nature of case: Appeal of action for damages in tort and breach of contract
Successful party: Apotex Inc. (in part)
Date of decision:
Case: Eli Lilly Canada Inc et al v Teva Canada Limited, 2017 FC 88
Drug: ZYPREXA® (olanzapine)
Nature of case: Action pursuant to section 8 of the Patented Medicines (Notice of Compliance) Regulations, SOR/93-133 (the Regulations)
Recent pharmaceutical cases in regulatory and intellectual property law have resulted in developments on several fronts, including:
In this paper, we review some of